Company intelligence / Profile preview
New Amsterdam Sciences, Inc.
Scottsdale, Arizona, United States
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 2
01
Overview
New Amsterdam Sciences is a clinical-stage bioscience company developing small molecule antioxidant SOD mimetics and peptide analogues of Substance P for indications including idiopathic pulmonary fibrosis, influenza, radiation exposure, progressive supranuclear palsy, and epilepsy. The company’s lead programs are in early clinical or preclinical development.
- Therapeutic areas
- NeurologyInfectious Diseases
- Modalities
- Small moleculesPeptide analogues
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on New Amsterdam Sciences, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on New Amsterdam Sciences, Inc..